CN106432057A - Method for preparing (3S)-3-(4-aminophenyl)-piperidyl-1-tert-butyl formate - Google Patents
Method for preparing (3S)-3-(4-aminophenyl)-piperidyl-1-tert-butyl formate Download PDFInfo
- Publication number
- CN106432057A CN106432057A CN201610826079.2A CN201610826079A CN106432057A CN 106432057 A CN106432057 A CN 106432057A CN 201610826079 A CN201610826079 A CN 201610826079A CN 106432057 A CN106432057 A CN 106432057A
- Authority
- CN
- China
- Prior art keywords
- aminophenyl
- piperidines
- butyl formate
- raceme
- tert
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 48
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 title abstract description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims abstract description 21
- 239000007787 solid Substances 0.000 claims abstract description 19
- 229940126062 Compound A Drugs 0.000 claims abstract description 18
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims abstract description 18
- 238000006460 hydrolysis reaction Methods 0.000 claims abstract description 14
- 238000001816 cooling Methods 0.000 claims abstract description 3
- COUOFYDJUDASPJ-SNVBAGLBSA-N 4-[(3s)-piperidin-3-yl]aniline Chemical class C1=CC(N)=CC=C1[C@H]1CNCCC1 COUOFYDJUDASPJ-SNVBAGLBSA-N 0.000 claims description 32
- 150000001875 compounds Chemical class 0.000 claims description 22
- 239000012046 mixed solvent Substances 0.000 claims description 17
- COUOFYDJUDASPJ-UHFFFAOYSA-N 4-piperidin-3-ylaniline Chemical class C1=CC(N)=CC=C1C1CNCCC1 COUOFYDJUDASPJ-UHFFFAOYSA-N 0.000 claims description 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 14
- -1 phosphate ester Chemical class 0.000 claims description 14
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 13
- 230000007062 hydrolysis Effects 0.000 claims description 13
- 229910019142 PO4 Inorganic materials 0.000 claims description 11
- 239000010452 phosphate Substances 0.000 claims description 11
- 239000002253 acid Substances 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 239000000376 reactant Substances 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 4
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 claims description 3
- 229910000024 caesium carbonate Inorganic materials 0.000 claims description 3
- 238000002425 crystallisation Methods 0.000 claims description 3
- 230000008025 crystallization Effects 0.000 claims description 3
- ISXSCDLOGDJUNJ-UHFFFAOYSA-N tert-butyl prop-2-enoate Chemical compound CC(C)(C)OC(=O)C=C ISXSCDLOGDJUNJ-UHFFFAOYSA-N 0.000 claims description 3
- 239000003513 alkali Substances 0.000 claims description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 2
- OVPROXCERHBLGN-UHFFFAOYSA-N 4-piperazin-2-ylaniline Chemical compound C1=CC(N)=CC=C1C1NCCNC1 OVPROXCERHBLGN-UHFFFAOYSA-N 0.000 claims 1
- BNBWOBMWJCGQCW-UHFFFAOYSA-N tert-butyl formate pyridine Chemical compound C(C)(C)(C)OC=O.N1=CC=CC=C1 BNBWOBMWJCGQCW-UHFFFAOYSA-N 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 abstract description 10
- 230000003287 optical effect Effects 0.000 abstract description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 abstract 1
- 230000002378 acidificating effect Effects 0.000 abstract 1
- 238000001914 filtration Methods 0.000 abstract 1
- 230000003301 hydrolyzing effect Effects 0.000 abstract 1
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 10
- 238000004128 high performance liquid chromatography Methods 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 238000010606 normalization Methods 0.000 description 9
- 238000001291 vacuum drying Methods 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 150000003053 piperidines Chemical class 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 239000002994 raw material Substances 0.000 description 6
- 239000002585 base Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000001953 recrystallisation Methods 0.000 description 5
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 4
- VMQMZMRVKUZKQL-UHFFFAOYSA-N Cu+ Chemical compound [Cu+] VMQMZMRVKUZKQL-UHFFFAOYSA-N 0.000 description 4
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000010949 copper Substances 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 239000003208 petroleum Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 101710179684 Poly [ADP-ribose] polymerase Proteins 0.000 description 3
- 102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 description 3
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 3
- YONLFQNRGZXBBF-ZIAGYGMSSA-N (2r,3r)-2,3-dibenzoyloxybutanedioic acid Chemical compound O([C@@H](C(=O)O)[C@@H](OC(=O)C=1C=CC=CC=1)C(O)=O)C(=O)C1=CC=CC=C1 YONLFQNRGZXBBF-ZIAGYGMSSA-N 0.000 description 2
- 102000011727 Caspases Human genes 0.000 description 2
- 108010076667 Caspases Proteins 0.000 description 2
- 229910021591 Copper(I) chloride Inorganic materials 0.000 description 2
- 230000005778 DNA damage Effects 0.000 description 2
- 231100000277 DNA damage Toxicity 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 239000012661 PARP inhibitor Substances 0.000 description 2
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000004296 chiral HPLC Methods 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 2
- UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- HJOQDQZVHDRCJH-UHFFFAOYSA-N naphthalen-1-ol;phosphoric acid Chemical compound OP(O)(O)=O.C1=CC=C2C(O)=CC=CC2=C1 HJOQDQZVHDRCJH-UHFFFAOYSA-N 0.000 description 2
- PCHKPVIQAHNQLW-CQSZACIVSA-N niraparib Chemical compound N1=C2C(C(=O)N)=CC=CC2=CN1C(C=C1)=CC=C1[C@@H]1CCCNC1 PCHKPVIQAHNQLW-CQSZACIVSA-N 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229910021589 Copper(I) bromide Inorganic materials 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 101150101566 Parp gene Proteins 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 230000004611 cancer cell death Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229950011068 niraparib Drugs 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- RUPAXCPQAAOIPB-UHFFFAOYSA-N tert-butyl formate Chemical group CC(C)(C)OC=O RUPAXCPQAAOIPB-UHFFFAOYSA-N 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
The invention discloses a method for preparing (3S)-3-(4-aminophenyl)-piperidyl-1-tert-butyl formate. The method is characterized by comprising the following steps: 1) performing a contact reaction on a 3-(4-aminophenyl)-piperidyl-1-tert-butyl formate racemate and (R)-(-)-binaphthyl-2,2-diyl hydrogen phosphate, cooling, crystallizing, and filtering to obtain a solid compound A; (2) hydrolyzing the solid compound A obtained in the step (1) under an acidic condition, adjusting the pH to be 8 to 10 after the hydrolysis reaction is completed, extracting with ethyl acetate, and concentrating to obtain the (3S)-3-(4-aminophenyl)-piperidyl-1-tert-butyl formate. The method provided by the invention is high in yield and high in product optical purity, and provides a new way for preparing the (3S)-3-(4-aminophenyl)-piperidyl-1-tert-butyl formate.
Description
Technical field
The invention belongs to medicinal chemistry art, and in particular to one kind prepares (3S) -3- (4- aminophenyl) piperidines -1- formic acid
The method of the tert-butyl ester.
Background technology
It is a targeted inhibition agent for PARP gene that Buddhist nun draws Pabuk (Niraparib), its chemical entitled 2- [4-
((3S) -3- piperidyl) phenyl] -2H- indazole -7- Methanamide, concrete structure formula is represented by a formula X.Buddhist nun draws Pabuk to be demonstrate,proved by clinic
In fact can be effective to kinds cancer, such as ovarian cancer, breast carcinoma, carcinoma of prostate etc..Buddhist nun draws Pabuk become second listing
PARP inhibitor, with huge potential using value.
PARP is the cutting substrate of apoptosis core member's caspase (caspase).It DNA damage reparation with
Play an important role in apoptosis.If DNA damage cannot be repaired, cell is possible to death.For with BRCA
For the cancerous cell of gene mutation, if PARP activity is suppressed further, a large amount of DNA during these cell divisions, will be produced
Damage, cause cancer cell death.And normal cell is because also BRCA is present, without PARP still can DNA plerosis, simply effect
Weaker, but can survive.Here it is PARP inhibitor is used as targeted drug, selectivity kills the original of BRCA mutated cancer cells
Cause.Buddhist nun draws Pabuk to be exactly based on this mechanisms play inhibitory action and carries out targeted therapy to cancerous cell, while avoiding to normal
The side effect of cell.
Draw preparing for Pabuk unsatisfactory currently for Buddhist nun, main using (3S) -3- (4- aminophenyl) piperidines -1- first
Tert-butyl acrylate is prepared as key intermediate, but by splitting acquisition (3S) -3- (4- aminophenyl) in prior art
The method of piperidines -1- t-butyl formate there are problems of yield low and.
Merck ＆ Co., Inc. Jones et al. is in pharmaceutical chemistry magazine (J Med Chem 2009,52 (22):7170-85) disclose
The preparation method of one kind (3S) -3- (4- aminophenyl) piperidines -1- t-butyl formate.The method is with 4- (piperidines -3- base) aniline
For raw material, with ethanol as solvent, L-TARTARIC ACID as resolving agent, split and obtain (S) -4- (piperidines -3- base) aniline, then pass through again
Boc protection obtains (3S) -3- (4- aminophenyl) piperidines -1- t-butyl formate, and concrete reaction equation is as follows：
But the method solvent load is big, and crystallization time is long, and yield is only 24% or so afterwards repeatedly to crystallize (three times),
And product ee value is only 80% or so.The method is extremely not suitable for industrialized production.
WO2008084261 discloses the preparation method of one kind (3S) -3- (4- aminophenyl) piperidines -1- t-butyl formate,
The method, with 4- (piperidines -3- base) aniline as raw material, is resolving agent through chiral separation system using L- dibenzoyl tartaric acid
For (S) -4- (piperidines -3- base) aniline is obtained, then product is obtained through Boc protection, reaction equation is as follows
But the method needs the resolving agent L- dibenzoyl tartaric acid using 2 times amount, high cost, tear open in the case
Divide yield still extremely low, repeatedly refined rear ee value is also only 80% or so.
Additionally, said method is also present is that Boc2O reacts using optical voidness (S) -4- (piperidines -3- base) aniline for obtaining
During still can with phenyl on amino reaction, cause optics pure products waste, and the by-product be not only difficult to separate and
And the reaction of subsequent intermediates can not be carried out.
Therefore, in view of Buddhist nun draws the good market prospect of Pabuk, this area still needs to a kind of high and fractionation selection of resolution yield
Property good Buddhist nun draw the chemical resolution preparation method of Pabuk intermediate (3S) -3- (4- aminophenyl) piperidines -1- t-butyl formate.
Content of the invention
The technical problem to be solved is：A kind of Buddhist nun is provided and draws Pabuk intermediate (3S) -3- (4- aminophenyl)
The chemical resolution preparation method of piperidines -1- t-butyl formate, the method resolution yield is high, optical purity of products height, without the need for special
Equipment, suitable large-scale production, is to prepare highly purified Buddhist nun further to draw Pabuk to provide raw material supply.
To achieve these goals, the invention discloses one kind prepares (3S) -3- (4- aminophenyl) piperidines -1- formic acid uncle
The method of butyl ester, the method is comprised the following steps：
1) by 3- (4- aminophenyl) piperidines -1- t-butyl formate raceme and (R)-(-)-dinaphthol phosphate ester connect
Reaction is touched, cooling crystallization, filters to obtain solid chemical compound A；
2) by step 1) the solid chemical compound A that obtains is hydrolyzed in acid condition, and will reaction after the completion of hydrolysis
Liquid adjusts pH to 8-10, and ethyl acetate is extracted, and concentrates, obtains (3S) -3- (4- aminophenyl) piperidines -1- t-butyl formate.
In the present invention, it is preferred in the case of, step 1) detailed process include：By 3- (4- aminophenyl) piperidines -1- first
Tert-butyl acrylate raceme and (R)-(-)-dinaphthol phosphate ester is added in mixed solvent, then heats to 75～85 DEG C of contacts anti-
Answer 1～2 hour, after haptoreaction, continue stirring and 45～50 DEG C of insulations 0.5～1 hour are naturally cooled to, then naturally cool to
Room temperature, is filtrated to get solid chemical compound A, and the mixed solvent is 3～8 by volume ratio：1 DMF is constituted with water.
In order to improve resolution yield, it is further preferred that the mixed solvent is 5～8 by volume ratio:1 DMF and water group
Become.With respect to every g 3- (4- aminophenyl) piperidines -1- t-butyl formate raceme, the consumption of the mixed solvent is 10-
20mL.
In step 1) in, under preferable case, 3- (4- aminophenyl) piperidines -1- t-butyl formate raceme and (R)-(-) -
The molar ratio of dinaphthol phosphate ester is 1：1～1.2.
The present inventor under study for action it has surprisingly been found that, in haptoreaction by add catalytic amount monovalence copper chemical combination
Thing, it is possible to increase (R)-(-) polarity effect of-dinaphthol phosphate ester, promote 3- (4- aminophenyl) piperidines -1- t-butyl formate
Raceme and (R)-(-) combination of-dinaphthol phosphate ester, copper (I) participates in the shape of solid chemical compound A with P and N Atomic coordinate
Become, optical selective and resolution yield is improved, it is therefore preferable that in the case of, step 1) it is additionally included in addition Cu in haptoreaction
(I) compound.Cu (I) compound can be CuCl, CuI or CuBr, preferably CuI.Under preferable case, Cu (I)
Compound is 1 with the molar ratio of 3- (4- aminophenyl) piperidines -1- t-butyl formate raceme：0.2～0.4.
In step 2) in, acid condition causes solid chemical compound A to occur hydrolysis that optics pure products are dissociated, the acidity
Condition should ensure that the abundant of hydrolysis will also be so that t-butyl formate protection group not be removed, it is preferred that the acid condition is referred to
Hydrolysis are carried out in 5～10% acid solutions, and the acid solution is preferably hydrochloric acid solution.After hydrolysis, (R)-(-)-connection
Naphthol phosphoric acid ester also can separate out, can by adjust the method such as pH and extraction be reclaimed.
Preferably, step 2) in the alkali that adjusts used by pH to 8-10 be sodium hydroxide, sodium carbonate or cesium carbonate.
Various raw materials can be obtained by conventional route in the present invention, such as 3- (4- aminophenyl) piperidines -1- formic acid
Tert-butyl ester raceme is commercially available or is prepared by prior art (such as WO2008084261)；(R)-(-)-connection
Naphthol phosphoric acid ester can also be commercially available.
In the present invention, the process of haptoreaction and hydrolysis can be monitored by conventional method, for example
TLC, HPLC, GC etc., haptoreaction or hydrolysis terminate to refer to that in reaction, excess raw material is not remaining less than 0.2%.Ability
(3S) -3- (4- amino that field technique personnel can be obtained to the method for the present invention through methods such as recrystallization according to actual needs
Phenyl) piperidines -1- t-butyl formate carries out conventional purification.
In the present invention, for the effect of the convenient description present invention, by a kind of enantiomer with respect to another kind
The amount of enantiomer is expressed as percent enantiomeric excess, and which is abbreviated as " %ee ".Percent enantiomeric excess can be according to
Following equation is calculated：%ee=[([A]-[B])/([A]+[B])] × 100, wherein [A] is a kind of content of enantiomer, and [B]
Content for another kind of enantiomer.
Compared with prior art, the present invention provides one kind and prepares (3S) -3- (4- aminophenyl) piperidines -1- t-butyl formate
New way, simple to operate, reaction is easy to get with raw material, and product yield and ee value are effectively improved.
Specific embodiment
The present invention is further described below by way of specific embodiment, the present invention is not limited only to following examples.At this
In bright scope or without departing from the change in present disclosure, spirit and scope, the present invention being carried out, combination or replacing
Change, will be apparent to the person skilled in the art, and be included within the scope of the present invention.
Embodiment 1
The method that one kind prepares (3S) -3- (4- aminophenyl) piperidines -1- t-butyl formate, the method includes following step
Suddenly：
1) by 3- (4- aminophenyl) piperidines -1- t-butyl formate raceme 27.6g (100mmol), (R)-(-)-dinaphthalene
Phenol phosphate ester 38.3g (110mmol), CuI3.8g (20mmol) are added in 150ml mixed solvent, and the mixed solvent is by body
Product is than being 5：1 DMF is constituted with water, then heats to 75 DEG C of haptoreactions 1 hour, after haptoreaction, continues stirring nature cold
But to 50 DEG C be incubated 1 hour, then naturally cool to room temperature, be filtrated to get solid chemical compound A.
2) by step 1) the solid chemical compound A that obtains is hydrolyzed in 10% hydrochloric acid solution of 50ml, and hydrolysis are completed
Add sodium hydroxide that reactant liquor is adjusted pH to 10 afterwards, ethyl acetate is extracted, and is concentrated, petroleum ether recrystallization, and vacuum drying is obtained
(3S) -3- (4- aminophenyl) piperidines -1- t-butyl formate 12.6g, yield 91.3%, HPLC purity (area normalization method)
99.91%, ee value, 99.57% (chiral HPLC (post：Chiralpak AD, 5x50cm；Eluent：10% ethanol/heptane；Pressure
Power：15bar；Flow velocity：35ml/min)).
Embodiment 2
The method that one kind prepares (3S) -3- (4- aminophenyl) piperidines -1- t-butyl formate, the method includes following step
Suddenly：
1) by 3- (4- aminophenyl) piperidines -1- t-butyl formate raceme 27.6g (100mmol), (R)-(-)-dinaphthalene
Phenol phosphate ester 41.8g (120mmol), CuI7.6g (40mmol) are added in 150ml mixed solvent, and the mixed solvent is by body
Product is than being 7：1 DMF is constituted with water, then heats to 80 DEG C of haptoreactions 1 hour, after haptoreaction, continues stirring nature cold
But to 45 DEG C be incubated 1 hour, then naturally cool to room temperature, be filtrated to get solid chemical compound A.
2) by step 1) the solid chemical compound A that obtains is hydrolyzed in 60ml5% hydrochloric acid solution, after the completion of hydrolysis
Add sodium hydroxide that reactant liquor is adjusted pH to 9, ethyl acetate is extracted, concentrate, petroleum ether recrystallization, vacuum drying is obtained
(3S) -3- (4- aminophenyl) piperidines -1- t-butyl formate 12.5g, yield 90.6%, HPLC purity (area normalization method)
99.64%, ee value 99.46%.
Embodiment 3
The method that one kind prepares (3S) -3- (4- aminophenyl) piperidines -1- t-butyl formate, the method includes following step
Suddenly：
1) by 3- (4- aminophenyl) piperidines -1- t-butyl formate raceme 27.6g (10mmol), (R)-(-)-dinaphthol
Phosphate ester 36.6g (105mmol), CuCl2.8g (30mmol) are added in 180ml mixed solvent, and the mixed solvent is by volume
Than for 8：1 DMF is constituted with water, then heats to 85 DEG C of haptoreactions 1.5 hours, after haptoreaction, continues stirring nature cold
But to 50 DEG C be incubated 0.5 hour, then naturally cool to room temperature, be filtrated to get solid chemical compound A.
2) by step 1) the solid chemical compound A that obtains is hydrolyzed in 50ml10% hydrochloric acid solution, and hydrolysis are completed
Add cesium carbonate that reactant liquor is adjusted pH to 8 afterwards, ethyl acetate is extracted, and is concentrated, petroleum ether recrystallization, and vacuum drying is obtained
(3S) -3- (4- aminophenyl) piperidines -1- t-butyl formate 12.4g, yield 90.2%, HPLC purity (area normalization method)
99.86%, ee value 99.53%.
Embodiment 4
The method that one kind prepares (3S) -3- (4- aminophenyl) piperidines -1- t-butyl formate, the method includes following step
Suddenly：
1) by 3- (4- aminophenyl) piperidines -1- t-butyl formate raceme 27.6g (100mmol), (R)-(-)-dinaphthalene
Phenol phosphate ester 38.3g (110mmol), CuI3.8g (20mmol) are added in 150ml mixed solvent, and the mixed solvent is by body
Product is than being 5：1 DMF is constituted with water, then heats to 75 DEG C of haptoreactions 1 hour, then naturally cools to room after haptoreaction
Temperature, is filtrated to get solid chemical compound A.
2) by step 1) the solid chemical compound A that obtains is hydrolyzed in 10% hydrochloric acid solution of 50ml, and hydrolysis are completed
Add sodium hydroxide that reactant liquor is adjusted pH to 10 afterwards, ethyl acetate is extracted, and is concentrated, petroleum ether recrystallization, and vacuum drying is obtained
(3S) -3- (4- aminophenyl) piperidines -1- t-butyl formate 11.4g, yield 82.6%, HPLC purity (area normalization method)
99.25%, ee value, 99.01% (chiral HPLC (post：Chiralpak AD, 5x50cm；Eluent：10% ethanol/heptane；Pressure
Power：15bar；Flow velocity：35ml/min)).
Embodiment 5
As embodiment 1 preparation (3S) -3- (4- aminophenyl) piperidines -1- t-butyl formate method, except that,
The mixed solvent is 1 by volume ratio：1 DMF is constituted with water.Vacuum drying obtains (3S) -3- (4- aminophenyl) piperidines -1-
T-butyl formate 11.8g, yield 85.7%, HPLC purity (area normalization method) 99.73%, ee value 99.60%.
Embodiment 6
As embodiment 1 preparation (3S) -3- (4- aminophenyl) piperidines -1- t-butyl formate method, except that,
It is added without CuI.It is vacuum dried and (3S) -3- (4- aminophenyl) piperidines -1- t-butyl formate 10.3g is obtained, yield 74.4%,
HPLC purity (area normalization method) 99.05%, ee value 98.29%.
Embodiment 7
As embodiment 1 preparation (3S) -3- (4- aminophenyl) piperidines -1- t-butyl formate method, except that,
CuI0.95g (5mmol) is added, vacuum drying obtains (3S) -3- (4- aminophenyl) piperidines -1- t-butyl formate 11.3g, receives
Rate 82.3%, HPLC purity (area normalization method) 99.33%, ee value 99.07%.
Embodiment 8
As embodiment 1 preparation (3S) -3- (4- aminophenyl) piperidines -1- t-butyl formate method, except that,
CuCl using same molar2CuI is substituted, vacuum drying obtains (3S) -3- (4- aminophenyl) piperidines -1- t-butyl formate
10.3g, yield 75.2%, HPLC purity (area normalization method) 98.37%, ee value 97.65%.
Embodiment 9
As embodiment 1 preparation (3S) -3- (4- aminophenyl) piperidines -1- t-butyl formate method, except that,
Step 2) be hydrolyzed in 25% hydrochloric acid solution reaction, and vacuum drying obtains (3S) -3- (4- aminophenyl) piperidines -1- formic acid
Tert-butyl ester 12.4g, yield 82.2%, HPLC purity (area normalization method) 96.31%, ee value 98.89%, wherein containing de-
Boc product 2.73%.
Comparative example 1
As embodiment 1 preparation (3S) -3- (4- aminophenyl) piperidines -1- t-butyl formate method, except that,
Using equivalent weight (S)-(+)-dinaphthol phosphate ester substitute (R)-(-)-dinaphthol phosphate ester, vacuum drying obtain faint yellow
Solid 10.2g, containing (3S) -3- (4- aminophenyl) piperidines -1- t-butyl formate 69.82%.
Claims (10)
1. the method that one kind prepares (3S) -3- (4- aminophenyl) piperidines -1- t-butyl formate, it is characterised in that the method bag
Include following steps：
1) by 3- (4- aminophenyl) piperidines -1- t-butyl formate raceme and (R)-(-)-dinaphthol phosphate ester carry out contacting anti-
Should, cooling crystallization, filter to obtain solid chemical compound A；
2) by step 1) the solid chemical compound A that obtains is hydrolyzed in acid condition, after the completion of hydrolysis adjusts reactant liquor
Section pH to 8-10, ethyl acetate is extracted, and is concentrated, is obtained (3S) -3- (4- aminophenyl) piperidines -1- t-butyl formate.
2. the method for claim 1, it is characterised in that step 1) detailed process include：By 3- (4- aminophenyl)
Piperidines -1- t-butyl formate raceme and (R)-(-)-dinaphthol phosphate ester is added in mixed solvent, then heat to 75～
85 DEG C of haptoreactions 1～2 hour, after haptoreaction, continue stirring and naturally cool to 45～50 DEG C to be incubated 0.5～1 hour, then
Room temperature is naturally cooled to, solid chemical compound A is filtrated to get, the mixed solvent is 3～8 by volume ratio：1 DMF is constituted with water.
3. method as claimed in claim 2, it is characterised in that the mixed solvent by volume ratio be:1 DMF and water
Composition.
4. method as claimed in claim 1 or 2, it is characterised in that step 1) it is additionally included in haptoreaction and adds Cu (I) to change
Compound.
5. method as claimed in claim 4, it is characterised in that Cu (I) compound be.
6. the method as described in claim 4 or 5, it is characterised in that Cu (I) compound and 3- (4- aminophenyl) piperazine
The molar ratio of pyridine -1- t-butyl formate raceme is 1：0.2～0.4.
7. method as claimed in claim 2 or claim 3, it is characterised in that with respect to every g 3- (4- aminophenyl) piperidines -1- formic acid
Tert-butyl ester raceme, the consumption of the mixed solvent is 10-20mL.
8. method as claimed in claim 1 or 2, it is characterised in that in step 1) in, 3- (4- aminophenyl) piperidines -1- first
Tert-butyl acrylate raceme and (R)-(-) molar ratio of-dinaphthol phosphate ester is 1：1～1.2.
9. method as claimed in claim 5, it is characterised in that step 2) acid condition refer to hydrolysis 5～10%
Carry out in acid solution, the acid solution is hydrochloric acid solution.
10. the method for claim 1, it is characterised in that step 2) in the alkali that adjusts used by pH to 8-10 be hydroxide
Sodium, sodium carbonate or cesium carbonate.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610826079.2A CN106432057A (en) | 2016-09-17 | 2016-09-17 | Method for preparing (3S)-3-(4-aminophenyl)-piperidyl-1-tert-butyl formate |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610826079.2A CN106432057A (en) | 2016-09-17 | 2016-09-17 | Method for preparing (3S)-3-(4-aminophenyl)-piperidyl-1-tert-butyl formate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106432057A true CN106432057A (en) | 2017-02-22 |
Family
ID=58168376
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610826079.2A Pending CN106432057A (en) | 2016-09-17 | 2016-09-17 | Method for preparing (3S)-3-(4-aminophenyl)-piperidyl-1-tert-butyl formate |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106432057A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019072237A1 (en) | 2017-10-13 | 2019-04-18 | Zai Lab (Shanghai) Co., Ltd. | Process for preparing intermediate of anti-tumor drug niraparib and intermediate thereof |
| US20220041575A1 (en) * | 2017-04-24 | 2022-02-10 | Tesaro, Inc. | Methods of manufacturing of niraparib |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009087381A1 (en) * | 2008-01-08 | 2009-07-16 | Merck Sharp & Dohme Ltd | Pharmaceutically acceptable salts of 2-{4-[(3s)-piperidin-3- yl]phenyl} -2h-indazole-7-carboxamide |
| WO2011076678A1 (en) * | 2009-12-22 | 2011-06-30 | F. Hoffmann-La Roche Ag | Substituted benzamide derivatives |
| CN103102280A (en) * | 2012-12-14 | 2013-05-15 | 中国科学院福建物质结构研究所 | Preparation method of optical pure 1-(alpha-amino benzyl)-2-naphthol |
| CN105085395A (en) * | 2014-05-07 | 2015-11-25 | 国药集团国瑞药业有限公司 | Preparation method for bedaquiline |
| CN105693605A (en) * | 2016-03-09 | 2016-06-22 | 西安科技大学 | Asymmetric synthesis method of optically pure (R)/(S)-chloroquine |
-
2016
- 2016-09-17 CN CN201610826079.2A patent/CN106432057A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009087381A1 (en) * | 2008-01-08 | 2009-07-16 | Merck Sharp & Dohme Ltd | Pharmaceutically acceptable salts of 2-{4-[(3s)-piperidin-3- yl]phenyl} -2h-indazole-7-carboxamide |
| WO2011076678A1 (en) * | 2009-12-22 | 2011-06-30 | F. Hoffmann-La Roche Ag | Substituted benzamide derivatives |
| CN103102280A (en) * | 2012-12-14 | 2013-05-15 | 中国科学院福建物质结构研究所 | Preparation method of optical pure 1-(alpha-amino benzyl)-2-naphthol |
| CN105085395A (en) * | 2014-05-07 | 2015-11-25 | 国药集团国瑞药业有限公司 | Preparation method for bedaquiline |
| CN105693605A (en) * | 2016-03-09 | 2016-06-22 | 西安科技大学 | Asymmetric synthesis method of optically pure (R)/(S)-chloroquine |
Non-Patent Citations (2)
| Title |
|---|
| DEBRA J.WALLACE,ET AL: "Development of a Fit-for-Purpose Large-Scale Synthesis of an Oral PARP Inhibitor", 《ORG.PROCESS RES.DEV.》 * |
| 杨善中: "《有机结构理论》", 31 January 2003, 合肥工业大学出版社 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220041575A1 (en) * | 2017-04-24 | 2022-02-10 | Tesaro, Inc. | Methods of manufacturing of niraparib |
| US11629137B2 (en) * | 2017-04-24 | 2023-04-18 | Tesaro, Inc. | Methods of manufacturing of niraparib |
| WO2019072237A1 (en) | 2017-10-13 | 2019-04-18 | Zai Lab (Shanghai) Co., Ltd. | Process for preparing intermediate of anti-tumor drug niraparib and intermediate thereof |
| US10927077B2 (en) | 2017-10-13 | 2021-02-23 | Zai Lab (Shanghai) Co., Ltd. | Process for preparing intermediate of anti-tumor drug niraparib and intermediate thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7377828B2 (en) | Method for preparing pyrimidinylcyclopentane compounds | |
| ME00155B (en) | 5-substituted quinoline and isoquinoline derivatives, a method for the production thereof and their use as antiphlogistics | |
| CN102108059A (en) | Method for synthesizing doxylamine succinate | |
| CN106432056A (en) | Preparation method of niraparib intermediate of (3S)-3-(4-aminophenyl) piperidine-1-tert-butyl formate | |
| CN106432057A (en) | Method for preparing (3S)-3-(4-aminophenyl)-piperidyl-1-tert-butyl formate | |
| EP3156391A1 (en) | Method for preparing sitagliptin intermediate via asymmetrical reduction method | |
| CN106631831A (en) | A method of preparing R-terbutaline | |
| CN103044468B (en) | Preparation method of N-(2-pyrazine carbonyl)-L-phenylalanine-L- leucine boracic acid | |
| CN109867673B (en) | Method for synthesizing palbociclib | |
| CN105859686A (en) | Preparation technology of high-purity dabigatran etexilate | |
| JP5305593B2 (en) | Preparation of highly chemical R-5- (2- (2-ethoxyphenoxyethylamino) propyl) -2-methoxybenzenesulfonamide hydrochloride | |
| CA3011662A1 (en) | An improved process for the preparation of regorafenib | |
| JPWO2014051077A1 (en) | Method for producing high purity nitrogen-containing heterocyclic compound | |
| CN107365301B (en) | Synthesis method of crizotinib and preparation method of intermediate thereof | |
| CN105130972A (en) | Emtricitabine benzoate, preparation method thereof, and method of preparing emtricitabine from emtricitabine benzoate | |
| CN106632038B (en) | A kind of method for splitting of octahydro isoquinolin | |
| CN114478303A (en) | A kind of synthetic method of carbidopa | |
| CN105646384A (en) | Refining method for enkephalin enzyme inhibitor and angiotensin II receptor antagonist eutectic compound | |
| JP2006028154A (en) | Method for producing optically active compound | |
| CN102816114B (en) | Preparation method of HMG-CoA reductase inhibitor | |
| WO2015012271A1 (en) | Method for producing heterocyclic compound | |
| CN109608398A (en) | A kind of preparation method of Edaravone | |
| CN104530000B (en) | A kind of preparation method of aldosterone synthase regulator intermediate | |
| CN107652269A (en) | Methanesulfonic acid fluorine imatinib purification of intermediate method | |
| CN106588878A (en) | Method for refining Esomeprazole sodium |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20170222 |